Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 17/20 | 0.54 |
| ▸ | PGR | P06401 | 14/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823422 | 0.87 | NR3C1 (0.52) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL14081376 | 0.84 | NR3C1 (0.59) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL563723 | 0.82 | NR3C1 (0.62) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL14081359 | 0.82 | NR3C1 (0.62) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL3690152 | 0.82 | NR3C1 (0.57) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL564457 | 0.81 | NR3C1 (0.54) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL14115126 | 0.81 | NR3C1 (0.61) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL14208907 | 0.80 | NR3C1 (0.54) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL14189082 | 0.79 | NR3C1 (0.59) | NR3C1NR3C2PGRPARP1PTGS1 | |
| SCHEMBL3957430 | 0.78 | NR3C1 (0.51) | NR3C1NR3C2PGRPARP1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844039-B1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AG (DE) | 2009-07-15 | — | — | EP | disclosed |
| EP-1844039-B1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AG (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| US-20080188666-A1 | LINEAR PHENYL-SUBSTITUTED INDAZOLES AND INDOLES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008088969-A2 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | BAUSCH & LOMB INCORPORATED (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171873-A1 | Synthesis of selected stereoisomers of certain substituted alcohols | BAUSCH & LOMB INCORPORATED | 2008-07-17 | — | — | US | disclosed |
| US-20080171873-A1 | Synthesis of selected stereoisomers of certain substituted alcohols | BAUSCH & LOMB INCORPORATED | 2008-07-17 | — | — | US | disclosed |
| WO-2008055710-A1 | INDOLE AND INDAZOLE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055709-A1 | INDAZOLE AND INDOLE DERIVATIVES AS ANTI -INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921068-A1 | Indazole and indole derivatives as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1921067-A1 | Indole and indazole derivatives as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1844039-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | disclosed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006050998-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | NFKBIA, PTGS2, PTGES2 | NR3C1 2604/4885NR3C2 1476/4885PGR 3086/4885 |
| US-20080171873-A1 | Synthesis of selected stereoisomers of certain substituted alcohols | ADH1A, ADH1C, ADH5 | NR3C1 74/4885NR3C2 37/4885PGR 3574/4885 |
| US-20080188666-A1 | LINEAR PHENYL-SUBSTITUTED INDAZOLES AND INDOLES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | IDO1, IL1B, IDO2 | NR3C1 1243/4885NR3C2 1183/4885PGR 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.